Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)
- Stass, Sanford — University of Maryland School of Medicine
- Dubinett, Steve — University of California, Los Angeles
- Massion, Pierre — Vanderbilt -Ingram Cancer Center
- Thornquist, Mark D — Fred Hutchinson Cancer Research Center
- Sidransky, David — Johns Hopkins University School of Medicine
- Srivastava, Sudhir — National Cancer Institute
- Rom, William — New York University School of Medicine
- Pass, Harvey Ira — New York University School of Medicine
- Spira, Avrum — Boston University
- Croce, Carlo — The Ohio State University Medical Center
The goal of this collaborative group study is to improve the diagnostic evaluation of patients with indeterminate pulmonary nodules by determining whether molecular biomarkers for lung cancer diagnosis, measured in minimally invasive and non-invasive biospecimens, are able to distinguish between patients with malignant or benign indeterminate pulmonary nodules that are incidentally detected on CT scan in high risk smokers. Achieving this goal would suggest that these biomarkers could also be applied in the setting of indeterminate pulmonary nodules that are detected as part of radiographic screening for lung cancer. Sensitive and specific biomarkers that discriminate between patients with malignant or benign indeterminate pulmonary nodules could spur early treatment and thereby improve lung cancer outcomes, while minimizing complications from diagnostic procedures in patients without lung cancer. Thus, this collaborative group proposal seeks to validate a series of molecular biomarkers (including mRNA, miRNA and proteomic signatures in the airway and blood) that have been developed by EDRN lung cancer investigators as effective diagnostic tools of lung cancer for patients with indeterminate pulmonary nodules
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.